Davidk Erickson News Today

Q2 2023 Net Revenue of $49.3 Million, Up 33% from Q2 2022Raises Full-Year 2023 Net Revenue Guidance to $185 to $195 MillionOn Track to Achieving Sustained Profitability with Existing Cash NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aes...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--$EOLS--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023, af...

Second Tranche of $50 Million Now Available Until December 31, 2023, Providing Continued Financial FlexibilityAll Other Facility Terms and Conditions Remain UnchangedCompany Continues to Expect Existing Cash to Fund Current Operations Through BreakevenNEWPORT BEACH, Calif.--(BUSINESS WIRE)--$EOLS--Evolus, Inc. (NASD...

Reported Sales Up 27% to $33.9 Million; Success of ‘Switch Your Tox’ Promotion Contributes to $3.5 Million Incremental Increase in Deferred Revenue Over Q2 and Understates Strength of Results‘Switch Your Tox’ Drives Record Consumer Rewards Redemptions and New Purchasing AccountsReiterates Full-Year 2022 Net Revenue...

Press release content from Business Wire. The AP news staff was not involved in its creation.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--$EOLS--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has further strengthened and diversified its Board of Directors with the appointment of digital and beauty inn...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Published: Dec 10, 2020 SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia ® system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond ® bre...